Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical ...
Chronic myeloid leukemia (CML) is a type of blood cancer. CML is Philadelphia chromosome-positive (Ph+) when pieces of chromosomes 9 and 22 break off and swap places. This creates a new abnormal ...
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor–Positive/HER2–Negative Early Breast Cancer: Real-World Evidence From a Large ...
Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...
A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age ...
Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.
Scemblix showed a 68% major molecular response rate at 48 weeks, outperforming tyrosine kinase inhibitors by 19%. Common side effects included rash, musculoskeletal pain, and fatigue, with laboratory ...
The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...
Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...
The Hematology Society of Taiwan yesterday said acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow, can progress quickly and aggressively and urged the government to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results